JPMorgan sees 100% upside in overlooked cancer drug stock
The bank just put a big number on a small biotech company, and the target rests on a newly launched drug.
The bank just put a big number on a small biotech company, and the target rests on a newly launched drug.
BELLINGS Intelligence Score: 10
Why it matters
This is a routine equity research update highlighting JPMorgan's bullish view on a small biotech stock, which is standard market commentary without broader credit-market implications.
Sources
TheStreet
JPMorgan sees 100% upside in overlooked cancer drug stock
The bank just put a big number on a small biotech company, and the target rests on a newly launched drug.